On Thursday, RBC (TSX:RY) Capital maintained its Sector Perform rating on Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), with a steady price target of $141.00. The firm acknowledged the strong performance of the company's stock this year, attributing it to several factors.
Notably, the impressive data from the company's product ™845, the anticipation of phase II data for ™568 muscarinic, and the robust commercial success of Ingrezza, which is protected by a patent until 2038, have all contributed to investor optimism. This patent protection is seen as establishing a significant valuation base due to the projected cash flows.
Despite the positive outlook on Ingrezza's near-term growth, RBC Capital voiced concerns regarding potential challenges. Specifically, the firm pointed out the drug's exposure to Medicare Part D and the possible future effects of price discounting as a result of the Inflation Reduction Act (IRA). While these issues may pose long-term risks, RBC's analysis suggests that varying scenarios of Medicare exposure could lead to a notable decrease in future revenue and earnings for Neurocrine Biosciences.
RBC Capital emphasized the importance of the company's pipeline success in maintaining cash flows and solidifying investor confidence in Neurocrine Biosciences as a stable, low-risk mid-cap entity. As the market awaits the upcoming phase II data for ™568, the firm remains neutral on the company's shares. This stance reflects a cautious approach to the potential risks and the critical role of pipeline developments in the company's valuation.
In other recent news, Neurocrine Biosciences has been the subject of several important developments. Wells Fargo (NYSE:WFC) reiterated its Overweight rating on Neurocrine Biosciences shares, following the presentation of updated data on the company's drug candidate, atumelnant. The firm's confidence in the stock's potential performance relative to the broader market was reinforced by the promising clinical data.
The company also announced positive results from its CAHtalyst Pediatric and Adult Phase 3 studies, indicating that its drug candidate crinecerfont met primary and key secondary endpoints in treating congenital adrenal hyperplasia.
Notably, the studies showed that crinecerfont effectively decreased androstenedione levels and allowed for lower glucocorticoid dosing while maintaining androgen control. These findings have supported two New Drug Application submissions to the U.S. Food and Drug Administration.
In terms of leadership, Neurocrine Biosciences announced the appointment of Kyle Gano, Ph.D., as the CEO-elect, set to take over in October 2024. Dr. Gano, currently serving as Chief Business Development and Strategy Officer, will succeed Kevin Gorman, Ph.D., the company's long-standing CEO who will retire but continue to serve on the Neurocrine Board of Directors.
Lastly, UBS increased the price target for Neurocrine Biosciences shares to $193 from the previous $174, reiterating a Buy rating on the stock. The firm's positive outlook is based on several factors, including the steady growth of Ingrezza, the anticipated successful launch of crinecerfont in 2025, and significant upcoming read-outs from two major schizophrenia pipeline projects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.